Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub

BidaskClub lowered shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a sell rating in a research report released on Wednesday.

A number of other research analysts have also commented on CPRX. Oppenheimer set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Thursday, November 29th. ValuEngine lowered shares of Catalyst Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, August 8th. HC Wainwright set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 22nd. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 10th. Finally, Cantor Fitzgerald set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $5.65.

Shares of CPRX opened at $2.30 on Wednesday. The stock has a market cap of $236.30 million, a PE ratio of -10.95 and a beta of 2.01. Catalyst Pharmaceuticals has a 52 week low of $2.18 and a 52 week high of $4.37.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.08). Sell-side analysts forecast that Catalyst Pharmaceuticals will post -0.3 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of CPRX. Acadian Asset Management LLC acquired a new position in Catalyst Pharmaceuticals in the second quarter worth about $476,000. Rhumbline Advisers raised its position in Catalyst Pharmaceuticals by 34.7% in the second quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 23,383 shares in the last quarter. Bank of New York Mellon Corp raised its position in Catalyst Pharmaceuticals by 15.7% in the second quarter. Bank of New York Mellon Corp now owns 274,813 shares of the biopharmaceutical company’s stock worth $858,000 after purchasing an additional 37,388 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Catalyst Pharmaceuticals by 12.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock worth $651,000 after purchasing an additional 23,500 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in Catalyst Pharmaceuticals by 295.7% in the second quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 284,409 shares in the last quarter. 49.61% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Read More: Google Finance Portfolio

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply